MX381719B - Compuestos cbd fluorados, composiciones y usos de los mismos. - Google Patents
Compuestos cbd fluorados, composiciones y usos de los mismos.Info
- Publication number
- MX381719B MX381719B MX2015008766A MX2015008766A MX381719B MX 381719 B MX381719 B MX 381719B MX 2015008766 A MX2015008766 A MX 2015008766A MX 2015008766 A MX2015008766 A MX 2015008766A MX 381719 B MX381719 B MX 381719B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- cbd compounds
- fluorinated
- compounds
- fluorinated cbd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750043P | 2013-01-08 | 2013-01-08 | |
| PCT/IL2014/050023 WO2014108899A1 (en) | 2013-01-08 | 2014-01-08 | Fluorinated cbd compounds, compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008766A MX2015008766A (es) | 2016-03-07 |
| MX381719B true MX381719B (es) | 2025-03-12 |
Family
ID=50272668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008766A MX381719B (es) | 2013-01-08 | 2014-01-08 | Compuestos cbd fluorados, composiciones y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9447019B2 (enExample) |
| EP (1) | EP2943463B1 (enExample) |
| JP (3) | JP6228230B2 (enExample) |
| CN (1) | CN105209424B (enExample) |
| AU (2) | AU2014206036B2 (enExample) |
| CA (1) | CA2935899C (enExample) |
| ES (1) | ES2894836T3 (enExample) |
| MX (1) | MX381719B (enExample) |
| WO (1) | WO2014108899A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2016293387A1 (en) * | 2015-07-16 | 2018-01-25 | Universidade De São Paulo - Usp | Flourinated CBD compounds, compositions and uses thereof |
| WO2021173130A1 (en) | 2020-02-26 | 2021-09-02 | Vitality Biopharma, Inc. | Novel cannabinoid glycosides and uses thereof |
| JP2018528977A (ja) | 2015-09-22 | 2018-10-04 | バイタリティ バイオファーマ インコーポレイテッドＶｉｔａｌｉｔｙ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． | カンナビノイドグリコシドプロドラッグおよび合成の方法 |
| MA43001A (fr) * | 2015-10-16 | 2021-04-07 | Impact Biosciences Corp | Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| CA3063186A1 (en) | 2017-05-09 | 2018-11-15 | Vitality Biopharma, Inc. | Antimicrobial compositions comprising cannabinoids and methods of using the same |
| EP3630145A4 (en) | 2017-05-31 | 2021-04-07 | Phytecs, Inc. | PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM |
| AU2018343256B2 (en) | 2017-09-28 | 2024-09-19 | Harmony Biosciences Management, Inc. | Treatment of Fragile X Syndrome with cannabidiol |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11458109B2 (en) | 2018-12-14 | 2022-10-04 | Zynerba Pharmaceuticals, Inc. | Treatment of 22Q11.2 deletion syndrome with cannabidiol |
| EP4069215A4 (en) | 2019-12-06 | 2024-01-17 | Jlabs Beauty LLC | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| EP4153306A4 (en) | 2020-05-22 | 2024-06-26 | Ilera Derm LLC | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL DISEASES |
| GB2642523A (en) * | 2024-07-12 | 2026-01-14 | Sonas Pharmaceuticals N I Ltd | Novel halogenated cannabinoid derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| MX2010001242A (es) * | 2007-07-30 | 2010-07-02 | Alltranz Inc | Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos. |
| US20120172339A1 (en) | 2009-07-10 | 2012-07-05 | Northeastern University | Angiogenic resorcinol derivatives |
| HRP20171236T1 (hr) | 2009-08-31 | 2017-10-20 | Zynerba Pharmaceuticals, Inc. | Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama |
| WO2012011112A1 (en) * | 2010-07-22 | 2012-01-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Non psychoactive cannabinoids and uses thereof |
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
-
2014
- 2014-01-08 AU AU2014206036A patent/AU2014206036B2/en active Active
- 2014-01-08 JP JP2015551255A patent/JP6228230B2/ja active Active
- 2014-01-08 CA CA2935899A patent/CA2935899C/en active Active
- 2014-01-08 US US14/759,689 patent/US9447019B2/en active Active
- 2014-01-08 MX MX2015008766A patent/MX381719B/es unknown
- 2014-01-08 CN CN201480012168.2A patent/CN105209424B/zh active Active
- 2014-01-08 WO PCT/IL2014/050023 patent/WO2014108899A1/en not_active Ceased
- 2014-01-08 ES ES14709750T patent/ES2894836T3/es active Active
- 2014-01-08 EP EP14709750.5A patent/EP2943463B1/en active Active
-
2016
- 2016-08-19 US US15/241,557 patent/US9782360B2/en active Active
-
2017
- 2017-08-01 US US15/666,128 patent/US10441553B2/en active Active
- 2017-10-12 JP JP2017198146A patent/JP2018065794A/ja active Pending
-
2018
- 2018-01-24 AU AU2018200570A patent/AU2018200570B2/en active Active
-
2019
- 2019-01-28 JP JP2019012349A patent/JP6952727B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170326078A1 (en) | 2017-11-16 |
| EP2943463B1 (en) | 2021-07-14 |
| AU2018200570A1 (en) | 2018-02-15 |
| US9447019B2 (en) | 2016-09-20 |
| EP2943463A1 (en) | 2015-11-18 |
| US10441553B2 (en) | 2019-10-15 |
| AU2014206036A1 (en) | 2015-08-13 |
| AU2014206036B2 (en) | 2017-11-02 |
| CN105209424A (zh) | 2015-12-30 |
| JP6228230B2 (ja) | 2017-11-08 |
| ES2894836T3 (es) | 2022-02-16 |
| WO2014108899A1 (en) | 2014-07-17 |
| JP2019073547A (ja) | 2019-05-16 |
| HK1214586A1 (zh) | 2016-07-29 |
| US9782360B2 (en) | 2017-10-10 |
| JP2018065794A (ja) | 2018-04-26 |
| CA2935899A1 (en) | 2014-07-17 |
| MX2015008766A (es) | 2016-03-07 |
| JP2016505614A (ja) | 2016-02-25 |
| AU2018200570B2 (en) | 2019-09-26 |
| US20170197904A1 (en) | 2017-07-13 |
| JP6952727B2 (ja) | 2021-10-20 |
| US20150344403A1 (en) | 2015-12-03 |
| CA2935899C (en) | 2021-08-31 |
| AU2014206036A2 (en) | 2016-06-16 |
| CN105209424B (zh) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381719B (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| MX2022011795A (es) | Moduladores de p2x7. | |
| CR20140259A (es) | Compuestos novedosos de benzopirano, composiciones y usos de los mismos | |
| LT2984166T (lt) | Kompozicijos, skirtos mpsi gydymui | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| MX2015012456A (es) | Compuestos heterociclicos y usos de los mismos. | |
| NI201400080A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201400178A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
| MX2019013645A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2015009719A (es) | Inhibidores benzoquinolona de vmat2. | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| NI201600015A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| MX2018000515A (es) | Compuestos fluorados de cbd, composiciones y usos de los mismos. | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| MX2016000219A (es) | Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos. | |
| CL2016000038A1 (es) | Piraxolo-piridinaminas sustituidas | |
| EA201591867A1 (ru) | Композиция лютеина, подходящая для составов детского питания | |
| BR112016008035A2 (pt) | composição, uso da composição | |
| CU24283B1 (es) | Composiciones farmacéuticas |